BTIG Reaffirms Their Hold Rating on T2 Biosystems (TTOO)

BTIG analyst Mark Massaro reiterated a Hold rating on T2 Biosystems (TTOOResearch Report) on August 19. The company’s shares closed yesterday at $0.12.

According to TipRanks, Massaro is an analyst with an average return of -1.5% and a 42.42% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Natera, DermTech, and Guardant Health.

Currently, the analyst consensus on T2 Biosystems is a Hold with an average price target of $0.14.

See the top stocks recommended by analysts >>

TTOO market cap is currently $22.67M and has a P/E ratio of -0.37.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

T2 Biosystems, Inc. engages in the development of proprietary technology platform. It offers the T2 Magnetic Resonance technology which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types. It products include T2Bacteria Panel, T2Candida Panel, T2Dx Instrument, AND T2MR Technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Read More on TTOO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More